-
Professor Liu Jian: New ADC drugs have created a new situation, and HER2 low thinking is in the ascendant
Time of Update: 2023-02-01
Tolaney has a negative view, mainly in the following aspects:(1) No unique clinicopathological featuresA study published in Lancet Oncol in 2021 combined patient data from four prospective neoadjuvant therapy clinical trials (including a total of 3512 patients, of which 2310 were included in the analysis) [4], aiming to compare the clinical and pathological features of HER2-low expression and HER2 0 breast cancer, found that HER2-low breast cancer included more HR-positive patients and fewer G3 patients.
-
2022 SABCS Professor Wang Shu: Analyze the therapeutic value of novel ADCs in HER2-low expression
Time of Update: 2023-02-01
*For medical professionals onlyThe new ADC has a wide range of layouts and is expected to fully cover people who benefit from breast cancer. With the establishment of the efficacy of antibody-drug con
-
Highlight the encirclement! T-DXd that ushered in a new era of ADCs
Time of Update: 2023-01-06
But now T-DXd has changed that result, and studies have found that T-Dxd in breast cancer patients with "low HER2 expression" is significantly better than the current standard of care: chemotherapy.
-
Highlight the encirclement! T-DXd that ushered in a new era of ADCs
Time of Update: 2023-01-06
But now T-DXd has changed that result, and studies have found that T-Dxd in breast cancer patients with "low HER2 expression" is significantly better than the current standard of care: chemotherapy.
-
Professor Zhou Jun: The new generation of ADC drugs has brought breakthroughs to the treatment
Time of Update: 2023-01-06
*For medical professionals onlyThe HERB study reveals the therapeutic potential of novel ADC drugs in biliary tract cancer (BTC). The prognosis of advanced biliary cancer is poor, and the treatment be
-
Professor Zhou Jun: The new generation of ADC drugs has brought breakthroughs to the treatment
Time of Update: 2023-01-06
*For medical professionals onlyThe HERB study reveals the therapeutic potential of novel ADC drugs in biliary tract cancer (BTC). The prognosis of advanced biliary cancer is poor, and the treatment be
-
2022 CSCO | Professor Zhou Caicun: Filling the gap to help the future, progress in HER2 diagnosis and treatment and new breakthroughs in ADC drugs
Time of Update: 2023-01-05
Novel ADC combined with immunization targeting TROP2 is expected to advance the treatment status of patients with high expression of PD-L1Professor Zhou CaicunShanghai Pulmonary Hospital Affiliated to Tongji UniversityThe TROPION-Lung02 study explored the efficacy and safety of Dato-DXd+ pembrolizumab ± platinum-containing chemotherapy (dual or triple-drug) for metastatic NSCLC.
-
ADC new drug R&D pattern in China
Time of Update: 2023-01-05
As of November 2022, NMPA has accepted a total of 80 new ADC drugs. Since 2020, the research and development of new ADC drugs in China has become popular and has entered a stage of explosive growth, w
-
New advances in ADC therapy for HER2-positive breast cancer brain metastases
Time of Update: 2022-12-04
IN THE PATRICIA STUDY, HIGH-DOSE PH DUAL-TARGETED THERAPY HAD A CERTAIN EFFICACY ON BREAST CANCER BRAIN METASTASIS, WITH A CNS ORR OF 11%, A CLINICAL BENEFIT RATE OF 68% AT 4 MONTHS, AND A CLINICAL BENEFIT RATE OF 51% AT 6 MONTHSSmall molecule TKI is a commonly used anti-HER2 therapeutic drug in clinical practice, and the activity of TKI in the treatment of brain metastases has also been explored in a number of clinical studies [5].
-
After ADC, can PDC become a new direction for targeted therapy?
Time of Update: 2022-11-26
As an anti-cancer drug delivery modality, PDCs have the advantage of covalently modifying a ligand peptide that can target specific cell surface receptors or biomarkers at the tumor site for long-lasting efficacy, thereby imparting an overall desirable pharmacokinetic profile.
-
The Magic Bullet to Cancer in the New Century takes stock of 14 ADCs available worldwide
Time of Update: 2022-11-04
Its constituent structure is conjugated by the chimeric antibody IgG1 targeting CD30 and the tubulin inhibitor MMAE via a protease-sensitive linker, Vat-Cit. The drug is mainly suitable for classical Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (sALCL), which was approved by the NMPA in China in 2020 for the treatment of patients with relapsed or refractory sALCL and CD30-positive HL, and is the second ADC approved for marketing in China.
-
Professors Wu Depei and Zhang Xi: Concentric relay, continuing hope, innovative ADC drug Pola opens
Time of Update: 2022-10-14
GuideEvery opening of the unknown world has the brave foresight of pioneers; Every journey of sneaking in the dark night, there is a little lamp man fearlessly leading the way. The series of reports "
-
ESMO is unstoppable in the field to hit the ADC, and a new generation is imminent
Time of Update: 2022-10-03
The study showed that ZW49 has a manageable safety profile with encouraging antitumor activity in HER2-positive cancer patients receiving multi-line therapy.
The study showed that ZW49 has a manageable safety profile with encouraging antitumor activity in HER2-positive cancer patients receiving multi-line therapy.
-
ADC drugs into a new blue ocean, domestic pharmaceutical companies are accelerating the layout!
Time of Update: 2022-09-30
It is worth noting that since First Third Gong Pharmaceutical licensed its two blockbuster products, DS-8201 and DS-1062, to AstraZeneca for more than $6 billion in 2019, the enthusiasm for the research and development of ADC drugs at home and abroad has reached a new height.
-
ADC drugs into a new blue ocean, domestic pharmaceutical companies are accelerating the layout!
Time of Update: 2022-09-30
It is worth noting that since First Third Gong Pharmaceutical licensed its two blockbuster products, DS-8201 and DS-1062, to AstraZeneca for more than $6 billion in 2019, the enthusiasm for the research and development of ADC drugs at home and abroad has reached a new height.